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Control of 5-Hydroxytryptamine Release in the Dorsal Raphe
Nucleus by the Noradrenergic System in Rat Brain. Role of
a-Adrenoceptors
A Bortolozzi1 and F Artigas*,1
1Department of Neurochemistry, Institut d’ Investigacions Biome`diques de Barcelona (CSIC), IDIBAPS, 08036 Barcelona, Spain
The interactions between the brainstem serotonergic (5-hydroxytryptamine, 5-HT) and noradrenergic (NA) systems are important for
the pathophysiology and treatment of affective disorders. We examined the influence of a-adrenoceptors on 5-HT and NA release in
the rat dorsal raphe nucleus (DR) using microdialysis. 5-HT and NA concentrations in DR dialysates were virtually suppressed by TTX
and increased by veratridine. The local and systemic administration of the a1-adrenoceptor antagonist prazosin reduced the DR 5-HT
output but not that of NA. The maximal 5-HT reduction induced by local prazosin administration (78% at 100mM) was more marked
than by its systemic administration (43% at 0.3 mg/kg). The local application of NA and desipramine, to increase the tone on DR
a1-adrenoceptors, did not enhance 5-HT release. The local (100 mM) or systemic (0.1–1 mg/kg s.c.) administration of clonidine reduced
5-HT and NA release (48 and 79%, respectively, at 1 mg/kg), an effect reversed by RX-821002, which by itself increased both amines
when given systemically. DSP-4 pretreatment prevented the effects of clonidine on 5-HT, suggesting the participation of
a2-adrenoceptors on NA elements. Moreover, the systemic effect of clonidine on 5-HT (but not NA) was cancelled by lesion of the
lateral habenula and by anesthesia, and was slightly enhanced by cortical transection. These data support the view that a1-adrenoceptors
in the DR tonically stimulate 5-HT release, possibly at nearly maximal tone. Likewise, the 5-HT release is modulated by a2-adrenoceptors
in NA neurons and in forebrain areas involved in the distal control of 5-HT neurons.
Neuropsychopharmacology (2003) 28, 421–434. doi:10.1038/sj.npp.1300061
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INTRODUCTION
The dorsal raphe nucleus (DR) of the midbrain contains
most serotonergic (5-hydroxytryptamine, 5-HT) neurons
that project to the forebrain (Dahlstro¨m and Fuxe, 1964). 5-
HT neurons are involved in many physiological functions
and are the cellular target of a large array of drugs used to
treat psychiatric illnesses (Jacobs and Azmitia, 1992;
Montgomery, 1994; Meltzer, 1999). In particular, the vast
majority of antidepressant drugs increase the serotonergic
activity by directly or indirectly interfering with the
mechanisms controlling the synaptic (extracellular) con-
centration of 5-HT, such as reuptake or deamination. Thus,
the selective serotonin reuptake inhibitors (SSRIs) represent
over 80% of the world antidepressant market (Heal and
Cheetham, 1997). However, antidepressant drugs that
inhibit noradrenaline (NA) reuptake as well may be more
effective than SSRIs in the treatment of depression (DUAG,
1986, 1990; Thase et al, 2001).
The activity of DR serotonergic neurones is tightly
controlled by 5-HT1A autoreceptors (Blier and de Montigny,
1987; Sprouse and Aghajanian, 1987) and by afferent
pathways from several brain areas (Jacobs and Azmitia,
1992). Among these, the catecholamine groups (Baraban
and Aghajanian, 1980; Peyron et al, 1996), the lateral
habenula (Aghajanian and Wang, 1977; Stern et al, 1981),
and the medial prefrontal cortex (Aghajanian and Wang,
1977; Sesack et al, 1989; Hajo´s et al, 1998; Peyron et al, 1998;
Celada et al, 2001; Martı´n-Ruiz et al, 2001a) play a major
role.
The anatomical relationships between the DR and the
pontine noradrenergic nuclei suggest the existence of a
functional interaction between noradrenergic and seroto-
nergic neurons. Both neuronal groups are REM-off (Aston-
Jones et al, 1991; Jacobs and Azmitia, 1992) and previous
studies have shown that the discharge rate and release of
serotonergic neurons is under the excitatory control of a1-
adrenoceptors (Baraban and Aghajanian, 1980; Pan et al,
1994). Thus, the a1-adrenoceptor agonist phenylephrine,
applied in the DR, reversed the cessation of serotonergic
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discharge occurring during REM sleep in cats (Sakai and
Crochet, 2000). Likewise, in deafferented midbrain slices
containing the DR, bath application of phenylephrine
restores normal firing in serotonergic neurons. On the
other hand, the activation of a2-adrenoceptors has been
shown to reduce the firing activity of serotonergic neurons
and the release of 5-HT in forebrain structures (Svensson et
al, 1975; Tao and Hjorth, 1992; Mongeau et al, 1997).
The interplay between both aminergic systems is likely
involved in common physiological aspects of serotonergic
and noradrenergic neurons, such as their parallel change of
activity across the sleep–wake cycle, which suggests
coordinate actions in the forebrain through the activation
of postsynaptic receptors. It is also likely that these
interactions play a role in the reported superior clinical
efficacy of antidepressants acting on both neurotransmitter
systems (DUAG, 1986, 1990; Thase et al, 2001). In an
attempt to better understand the control of the serotonergic
system by noradrenergic inputs, we recently examined the
effects of a1- and a2-adrenoceptor ligands on the release of
5-HT in the median raphe nucleus (Adell and Artigas, 1999).
Here we extend our study to examine the effects of
modulating a1- and a2-adrenoceptor-mediated transmission
on the release of 5-HT and NA in the DR of the freely
moving rat using in vivo microdialysis.
MATERIALS AND METHODS
Animals
Male Wistar rats (Iffa Credo, Lyon, France) weighing 280–
320 g at the beginning of the experiments were used. The
animals were housed in groups of four per cage until the
onset of the experiments, and kept under a controlled
temperature of 227 21C and a 12 h lighting cycle (lights on
at 07:00). After surgery, rats were housed individually. Food
and water were always freely available throughout the
experiments. All experimental procedures were in strict
compliance with the Spanish legislation and the European
Communities Council Directive on ‘Protection of Animals
Used in Experimental and Other Scientific Purposes’ of 24
November 1986 (86/609/EEC).
In Vivo Microdialysis
Concentric microdialysis probes were constructed with
20 mm long 25-gauge stainless-steel tubing (A-M Systems,
Everett, WA, USA). The inflow and outflow lines inserted
into the 25-gauge tubing consisted of a fused silica capillary
tubing of 110 mm OD and 40 mm ID (Polymicro Technolo-
gies, Phoenix, AZ, USA). Dialysis membranes were made
from hollow cuprophan fibers with 252 mm OD, 220 mm ID
and 5000 Da molecular weight cutoff (GFE09, Gambro,
Lund, Sweden). The total length of the dialysis membrane
exposed to the tissue was 1.5 mm in the DR and 4 mm in the
dorsal striatum. To reduce the void volume, narrow-bore
(0.15 mm ID) FEP tubing (Metalant AB, Stockholm,
Sweden) was used in the microdialysis system. After an
injection of 60 mg/kg of sodium pentobarbital, the rats were
placed in a stereotaxic frame (David Kopf Instruments,
Tujunga, CA, USA) and a dialysis probe was implanted in
the DR and secured to the skull with anchor screws and
dental cement. Stereotaxic coordinates (in mm) from
bregma and skull surface were AP 7.8, L 3.1, DV 7.5,
with a lateral angle of 301 to avoid obstruction of the
cerebral aqueduct, for the DR, and AP +0.2, L 3.0, DV
8.0 for dorsal striatum (Paxinos and Watson, 1986). After
a recovery period of 20–24 h, rats were placed in a plastic
cage with a mounted liquid swivel system (Instech
Laboratories, Plymouth Meeting, PA, USA). The probes
were perfused at a constant rate of 1.5 ml/min with an
artificial cerebrospinal fluid (aCSF; NaCl 125 mM, KCl
2.5 mM, MgCl2 1.18 mM, and CaCl2 1.26 mM), containing
1mM of citalopram (H Lundbeck A/S, Copenhagen-Valby,
Denmark). The dialysate level of 5-HT represents a balance
between release and reuptake of the transmitter. With the
partial blockade of the reuptake process by the addition of
citalopram to the perfusion fluid, the concentration of 5-HT
in dialysate samples reflects mainly the release of the
transmitter. Dialysate samples of 30 ml were collected at 20-
min intervals into polypropylene microcentrifuge vials
containing 5ml of 10 mM perchloric acid. After an initial
1 h sample of dialysate was discarded, four samples were
collected to establish stable baseline levels of 5-HT and NA.
HPLC Analysis
Dialysate samples were assayed for 5-HT and NA by HPLC
using an Ultrasphere 3 mm column (7.5 cm 0.46 cm;
Beckman, San Ramon, CA, USA) and determined with an
amperometric detector Hewlett-Packard 1049 (Palo Alto,
CA, USA), set at a potential of +0.75 V. Samples were
processed immediately after collection to prevent degrada-
tion of NA. The mobile phase consisted of 0.1 M KH2PO4,
2.3 mM octyl sodium sulfate, 0.1 mM EDTA (pH 2.6
adjusted with phosphoric acid) and 15% methanol, and
was pumped at 0.5 ml/min. With these conditions, the
respective retention times of NA and 5-HT were 3.5 and
16 min, approximately (Figure 1a).
In experiments involving lesions of the noradrenergic
system with DSP-4, rats were killed at the conclusion of the
dialysate experiments, and brain tissue processed according
to a method described elsewhere (Adell et al, 1989) to
examine the magnitude of NA depletion. Briefly, each brain
was quickly removed and placed over a cold plate. Coronal
cuts were made with a blade and the frontal cortex was
dissected out. Tissue samples were weighed and homo-
genized in 800 ml of ice-cold 0.4 mM perchloric acid
containing 5.0 mM sodium metabisulfite, 8.3 mM cysteine,
and 0.3 mM EDTA. After centrifugation at 12 000g (30 min,
41C), aliquots of the supernatants were analyzed for NA and
5-HT.
Chemicals
The HPLC reagents were of analytical grade and obtained
from Merck (Darmstadt, Germany). 5-HT oxalate, 8-OH-
DPAT ((7 )-8-hydroxy-2-(di-n-propylamino)tetralin hy-
drobromide), clonidine hydrochloride, desipramine
hydrochloride, DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromo-
benzylamine hydrochloride), NA bitartrate, prazosin hydro-
chloride, tetrodotoxin (TTX), veratridine, WAY-100635
(N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyr-
idinyl) cyclohexanecarboxamide trihydrochloride), and
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yohimbine hydrochloride were purchased from Sigma/RBI
(St Louis, MO, USA). RX-821002 (2-(2,3-dihydro-2-meth-
oxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole hy-
drochloride) was from Tocris (Bristol, UK). Citalopram
was gently provided by Lundbeck A/S (Copenhagen-Valby,
Denmark). Drugs were systemically administered at the doses
and routes indicated or locally applied by reverse dialysis at
the stated concentrations after appropriate dilutions in the
dialysis fluid. The DSP-4 solutions were prepared immedi-
ately before use. Concentrated (1 mM) drug solutions were
stored at 801C and working solutions were prepared every
day. When necessary, the pH of the concentrated solutions
was adjusted to B6–7. Control groups for the effects or
systemic drug administration were injected with vehicle
whereas controls for local drug administration were perfused
with aCSF for the entire experiment.
At the conclusion of the experiments, rats were given an
overdose of sodium pentobarbital, and the placement of the
dialysis probes was examined by perfusing fast green dye
and visual inspection of the probe track after cutting the
brain at the level of the DR or striatum.
Brain Lesions
To examine the involvement of a-adrenoceptors outside the
DR in the actions of clonidine and prazosin, we performed
several lesions. These included the treatment with the
noradrenergic neurotoxin DSP-4, the electrolytic lesion of
the lateral habenula, known to control the DR through the
habenulo–raphe pathway, and cortical transection, to
remove direct afferents from the medial prefrontal cortex
that control the activity of 5-HT and NA neurons
(Aghajanian and Wang, 1977; Stern et al, 1981;
Hajo´s et al, 1998; Jodo et al, 1998; Celada et al, 2001). The
lesion of the NA system was carried out by administration
of DSP-4 (40 mg/kg i.p.) 60 min after the injection of the
selective serotonin uptake inhibitor fluoxetine (10 mg/kg
i.p.), to prevent concurrent damage of serotonergic neurons
(Tellez et al, 1999). Rats were used 5–6 days after DSP-4
treatment.
Bilateral electrolytic lesions of the lateral habenula were
performed with a Grass stimulating unit S-48 using bipolar
electrodes (the distance between electrodes was 0.7 mm). A
current intensity of 2 mA for 10 s was used to produce the
lesions. Stereotaxic coordinates for the placement of
electrodes were AP 3.5, L 7 0.6, DV 4.8 (tip).
Transection of the frontal cortex was performed using a
fine needle (0.6 mm diameter), which was stereotaxically
positioned at AP +1.0, DV 6.0, L from 0.0 to 4.0, in sodium
pentobarbital (60 mg/kg i.p.) anesthetized rats. The needle
was moved from the midline bilaterally (from 0.0 to 7 4.0)
without damaging the sinus. Drug administration was
performed 22–24 h after the frontocortical transection. At
the end of microdialysis experiments, rats were killed with
an overdose of sodium pentobarbital and perfused trans-
cardially with 0.9% physiological saline followed by 10%
formalin. The brains were removed and stored in 10%
formalin before being sectioned (40 mm) with a cryostat in
the coronal or sagital plane. Brain sections were then
stained with neutral red, according to standard procedures
to examine the extent of the habenular lesions and
frontocortical transections.
Figure 1 (a) HPLC trace of a baseline dialysate sample from the DR showing the presence of NA and 5-HT (approximate retention times 3.5 and 16 min,
respectively). The absolute values for both neurotransmitters in this particular sample were 8.5 and 27 fmol, respectively. (b) Bar graph showing the effects of
the local perfusion of veratridine (10 mM) and tetrodotoxin (1 mM) on the concentration of 5-HT and NA in DR dialysates (n¼ 5). (c) and (d ) Effect of the
administration of the respective autoreceptor agonists 8-OH-DPAT (0.3 mg/kg s.c.; n¼ 5) and clonidine (0.1 mg/kg s.c.; n¼ 8) on dialysate 5-HT and NA,
respectively. The enhancement of NA output by 8-OH-DPAT is also shown. *po0.01 vs baseline.
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Data Treatment and Statistical Analysis
Baseline 5-HT and NA values are given in fmol/30 ml and
were calculated averaging the four predrug samples. Unless
otherwise specified, all samples were expressed as a
percentage of the mean baseline. In some instances, the 5-
HT or NA values have been averaged to examine drug effect
over a certain time period, indicated in the text. Overall
drug effects have been assessed by one- or two-way repeated
measures ANOVA with treatment and time as main factors.
One-way ANOVA or Student’s t-test for independent data
have also been used. All statistical procedures were
performed using the Statistica software for Windows
(StatSoft, Inc., Tulsa, OK, USA). Data are given as means
7 SEM. Statistical significance was set at the 95% level
(two-tailed).
RESULTS
Sensitivity of Dialysate 5-HT and NA in the DR to Nerve
Impulse
Figure 1a shows a typical HPLC trace of a dialysate
sample from the DR. Both the NA and 5-HT peaks
were free from interfering compounds. In order to
validate the HPLC method, we examined the sensitivity of
the 5-HT and NA peaks to the local application of
veratridine and TTX. The local application of veratridine
(10 mM) for 20 min doubled the concentration of 5-HT
(n¼ 5, po0.01, Duncan test post-ANOVA, Figure 1b).
Following stabilization of the 5-HT values, we applied
TTX (1 mM) for 2 h. TTX rapidly reduced dialysate 5-HT
concentration toB20% of baseline values from 40 min after
application onwards (po0.01, Duncan test post-ANOVA,
Figure 1b). Veratridine increased dialysate NA to an
extent similar to that of 5-HT (n¼ 5, po0.002, Duncan test
post-ANOVA) and TTX reduced it maximally to B20% of
baseline (po0.001, Duncan test post-ANOVA, Figure 1b).
Furthermore, the treatment of rats with 8-OH-DPAT
(0.3 mg/kg s.c., n¼ 5) and clonidine (0.1 mg/kg s.c.,
n¼ 8), agonists of 5-HT1A and a2-adrenoceptors,
respectively, markedly reduced the concentration of 5-HT
and NA in DR dialysates to ca. 25 and 50% of baseline,
respectively (F15,60¼ 7.95, po0.00001 and F15,45¼ 9.82,
po0.00001 for 8-OH-DPAT and clonidine, respectively,
Figures 1c and d). Baseline 5-HT and NA values in
dialysates from the DR of rats without pretreatment are
shown in Table 1.
Table 1 Effects of DSP-4 Pretreatment, Electrolytic Lesion of
Lateral Habenula and Cortical Transection on Baseline 5-HT and
NA Dialysate Values in the DR
Group
Baseline 5-HT
(fmol/fraction)
Baseline NA
(fmol/fraction)
No pretreatment 35.587 1.42 (105) 9.637 0.58 (74)
DSP-4 24.327 1.45** (31) 15.477 2.18* (29)
Lateral habenula-lesioned 25.917 2.13 (14) 9.807 0.40 (14)
Cortical transection 25.307 1.27 (14) 13.537 0.55 (14)
Data are means7 SEM of the number of animals shown in brackets.
*po0.05; **p¼ 0.06 with respect to nonlesioned animals (Tukey test post-
ANOVA).
Figure 2 Effect of the systemic (a, b) and local (c, d) administration of the a1-adrenoceptor antagonist prazosin on the 5-HT and NA output in the DR.
Prazosin reduced the 5-HT release at the three doses examined and did not affect NA. Note the absence of a linear dose–response in the effect of systemic
prazosin on 5-HT (a). The administration of prazosin by reverse dialysis in the DR (100 mM, uncorrected for probe recovery) markedly reduced the 5-HT
output (c) and did not affect NA output (d). (c) Results of two different experiments performed 10 months apart. Data from 4 to 8 rats/group except
prazosin 3 mg/kg (n¼ 3). See results for statistical analysis.
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Modulation of 5-HT Release by a1-Adrenoceptors
The systemic administration of prazosin (0.3 mg/kg s.c.)
reduced maximally the 5-HT output in the DR to 60% of
baseline without altering that of NA (Figures 2a and b). The
administration of saline did not significantly alter the
release of either transmitter. Two-way ANOVA showed a
significant effect of the time (F15,165¼ 12.1, po0.000001)
and the time treatment interaction (F15,165¼ 5.8,
po0.000001) for 5-HT. Prazosin (0.3 mg/kg s.c.) reduced
the 5-HT output similarly when probes were perfused with
an aCSF devoid of citalopram. Thus, the average reductions
(fractions 6–16) were 697 4 and 707 4% of baseline in the
presence and absence of citalopram, respectively (n.s.,
Student’s t-test). Higher doses of prazosin (1 and 3 mg/kg)
did not reduce 5-HT further (Figure 2a). Thus, prazosin
1 mg/kg reduced 5-HT to the same extent as 0.3 mg/kg,
whereas the 5-HT reduction produced by the 3 mg/kg dose
was less marked than that of 0.3 and 1 mg/kg (Figure 2a).
The local application of 100 mM prazosin in the DR, a
concentration known to maximally reduce 5-HT output in
the MnR (Adell and Artigas, 1999), reduced that in the DR
to 227 3% of baseline (Figure 2c). Two-way ANOVA
revealed a significant effect of the treatment (F1,11¼ 5.7,
po0.04) time (F11,165¼ 15.4, po0.000001) and the time-
 treatment interaction (F11,165¼ 10.7, po0.000001). Given
the marked difference between the local and systemic effect
of prazosin on the 5-HT output, we performed a second
local experiment several months later, which yielded exactly
the same results (Exp. 2, Figure 2c). Prazosin infusion did
not significantly alter the NA output in the DR (Figure 2).
These results support the fact that a1-adrenoceptors
tonically stimulate the 5-HT release in the DR. To examine
whether 5-HT output could be further enhanced by an
increased noradrenergic tone, we locally infused the NA
reuptake blocker desipramine in the DR. In the dorsal
striatum, desipramine (10100 mM) increased the NA
output to B5-fold of baseline (F21,126¼ 23.2, po0.00001,
one-way ANOVA) without significantly altering the 5-HT
output (Figure 3a). We therefore used 100 mM desipramine
in subsequent experiments in the DR. Desipramine perfu-
sion in the DR significantly increased the NA output to a
maximal concentration of 2167 25% of baseline (fractions
1–10, F9,27¼ 7.5, po0.00002) without significantly affecting
the 5-HT output (fractions 1–10, F9,27¼ 0.9, p¼ 0.55). The
subsequent co-application of prazosin did not alter the
effect of desipramine on NA output and significantly
reduced the 5-HT output to 487 9% of baseline (fractions
7–16, F9,27¼ 9.1, po0.0000003) (Figure 3b). A further
attempt to increase the tone on a1-adrenoceptors was
carried out by locally perfusing 10 nM NA in addition to
desipramine. This procedure maximally enhanced dialysate
NA 15-fold (data not shown) but did not alter the 5-HT
output in the DR (Figure 3c). As in previous experiments,
the application of 100 mM prazosin significantly reduced the
5-HT output (fractions 7–16, F9,27¼ 3.5, po0.005).
Modulation of 5-HT Release by a2-Adrenoceptors
The systemic administration of clonidine (0.1 and 1 mg/kg
s.c.) reduced the 5-HT output in the DR in a dose-
dependent manner (F15,225¼ 16.85, po0.0000001, time
effect; F30,225¼ 4.59, po0.000001, time group interaction)
(Figure 4a). In a pilot experiment, a lower dose (0.03 mg/kg
s.c.) did not alter the 5-HT output (data not shown). The
maximal reduction was noted at 1 mg/kg, reaching 527 5%
of baseline.
Clonidine administration also reduced the NA output in
the DR in a dose-dependent manner (F2,14¼ 5.64, po0.01,
group effect; F15,210¼ 17.42, po0.000001, time effect;
F30,210¼ 3.66, po0.000001, time group interaction). The
effect on NA was notably more marked than that on
Figure 3 (a) The application of desipramine (10–100 mM, 6 fractions
each) in the dorsal striatum increased the NA output in a concentration-
dependent manner and did not alter the 5-HT output. (b) In the DR, the
perfusion of desipramine also increased the NA output without significantly
affecting 5-HT. The subsequent co-perfusion of prazosin (100 mM)
significantly reduced the 5-HT output. (c) The perfusion of desipramine
100 mM in combination with 10 nM NA did not alter the 5-HT output in
the DR. As in previous experiments, the perfusion of prazosin markedly
reduced the 5-HT output. Data from 4 to 7 rats/group. See results for
statistical analysis.
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5-HT, with a maximal reduction to 18% of baseline at 1 mg/
kg (Figure 4b).
The effect of clonidine (0.1 mg/kg) on 5-HT and NA
output in the DR was antagonized by the selective
a2-adrenoceptor antagonist RX-821002 (1 mg/kg s.c.)
(po0.000001 vs clonidine alone for both amines). The
latter compound raised by itself the 5-HT and NA output to
1857 16 and 1807 21% of baseline, respectively
(po0.000001 vs controls for both amines) (Figures 4c and
d). In contrast, the a2-adrenoceptor antagonist yohimbine
(5 mg/kg i.p.) reduced the 5-HT output toB45% of baseline
(F15,105¼ 2.50, po0.0035, time effect; F15,105¼ 2.45,
po0.005, time group interaction) (Figure 5). However,
this effect appeared unrelated to an action at a2-adreno-
ceptors because the 5-HT1A receptor antagonist WAY-
Figure 4 Effects of the s.c. administration of the a2-adrenoceptor agonist clonidine on the output of 5-HT and NA in the DR: (a) reduction of the 5-HT
output produced by the s.c. administration of 0.1 and 1 mg/kg clonidine; (b) effect of the same clonidine doses on the NA output; (c) and (d) effect of the a2-
adrenoceptor antagonist RX-821002 (1 mg/kg s.c.) alone or in combination with clonidine 0.1 mg/kg s.c. on the 5-HT and NA output in the DR. RX-821002
significantly increased 5-HT and NA concentrations and fully antagonized the effect of clonidine on both amines. Controls (open circles) received saline.
Data from 5 to 8 rats/group. See results for statistical analysis.
Figure 5 The a2-adrenoceptor antagonist yohimbine (5 mg/kg i.p.)
markedly reduced 5-HT output in the DR. This effect was fully
counteracted by the selective 5-HT1A receptor antagonist WAY-100635
(0.3 mg/kg s.c.), indicating that the reduction produced by yohimbine was
because of nonspecific action at 5-HT1A receptors. Data from 4 rats/group.
See results for statistical analysis.
Figure 6 Effect of the local application of 100 mM clonidine on the 5-HT
and NA output in the DR. The 5-HT data correspond to two different
experiments employing two different HPLC methods. Filled symbols
(circles, 5-HT; squares, NA, n¼ 5) are from the same dialysate samples, as
in previous figures. The open circles correspond to a second experiment in
which the concentration of 5-HT in dialysate samples was determined using
a standard HPLC procedure (n¼ 6) (see the Materials and methods
section). The 5-HT values from both experiments did not significantly differ.
Clonidine was notably more effective to reduce the output of NA than that
of 5-HT.
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100635 (0.3 mg/kg s.c.) fully counteracted the yohimbine-
induced decrease in 5-HT (F15,90¼ 3.27, po0.0025 vs
yohimbine alone) (Figure 5), suggesting that the agonist
properties of yohimbine for 5-HT1A receptors were involved
(Millan et al, 2000).
The local administration of clonidine (100 mM) in the DR
reduced maximally the NA output to 307 5% of baseline
(F1,7¼ 52.5, po0.0002, group effect; F15,105¼ 3.8,
po0.00002, time effect; F15,105¼ 5.5, po0.00001, time-
 group interaction, Figure 6). However, the effect on the
5-HT output was more moderate, reaching only a 70–75% of
baseline (Figure 6). A second experiment was carried out in
which the local effect of clonidine on 5-HT was assessed
using a standard HPLC procedure (eg Adell and Artigas,
1998). The effects of this second experiment are also
depicted in Figure 6. A two-way ANOVA analysis did not
reveal any significant difference between the data of both
experiments, and therefore they were pooled and analyzed
together. The effect of local clonidine on the 5-HT output
showed a significant effect of time (F15,210¼ 3.6, po0.00002)
and the time group interaction (F15,210¼ 1.9, po0.03).
Effects of Lesions on the Modulation of the 5-HT Output
by a-Adrenoceptors
To examine the possible involvement of a-adrenoceptors
outside the DR in the control of the 5-HT output, several
lesion procedures were carried out in order to eliminate or
reduce the putative influence of such receptors on the
systemic effects of prazosin and clonidine. Three types of
lesions were performed, namely lesions of noradrenergic
neurons with the selective neurotoxin DSP-4, electrolytic
lesions of the lateral habenula, and cortical transections.
Groups of rats were pretreated with the noradrenergic
neurotoxin DSP-4 (40 mg/kg i.p., 5 days before experi-
ments). The concentration of 5-HT and NA in the frontal
cortex of control rats was 2487 12 and 3327 17 pmol/g,
respectively (n¼ 10). Rats pretreated with DSP-4 showed a
very marked reduction of the tissue NA content
(287 4 pmol/g, 11% of controls, po0.00001) without a
significant change of the 5-HT concentration
(2547 20 pmol/g; n¼ 19). Table 1 shows the baseline
concentrations of 5-HT and NA in DR dialysates of
untreated rats and in those subjected to the various lesion
procedures.
Modulation of the Effects of Prazosin Figure 7 shows the
local effect of prazosin on the 5-HT and NA output in the
DR of previously untreated rats and in rats subjected to the
above lesions. Rats lesioned with DSP-4 had significantly
lower values of dialysate 5-HT compared with the respective
control group (21.37 5.4 vs 39.87 5.8 fmol/fraction in
DSP-4 (n¼ 10) and untreated rats (n¼ 12), respectively;
po0.03). This difference was marginally significant
(p¼ 0.06) when considering all untreated rats used in the
present study (Table 1). The local administration of
prazosin reduced dialysate 5-HT in both groups, although
the effect was significantly less marked in DSP-4-lesioned
rats (F15,300¼ 35.71, po0.000001, time effect; F15,300¼ 6.16,
po0.0000001, time group interaction). In neither group
prazosin application altered the dialysate NA concentration
in the DR (Figure 7).
However, neither DSP-4 pretreatment nor the lesion of
the lateral habenula or the cortical transection altered the
effect of systemic prazosin (0.3 mg/kg s.c.) on the DR 5-HT
output in a significant manner (F15,315¼ 32.7, po0.000001,
significant effect of time but not of the group or group-
 time interaction). The average post-treatment values
(fractions 6–16) were 697 4 (n¼ 8), 707 5 (n¼ 6), 767 4
(n¼ 7), and 707 2 (n¼ 4) for controls, DSP-4-lesioned,
lateral habenula-lesioned, and cortically transected rats,
respectively (n.s., one-way ANOVA) (Figure 8a). Neither
condition altered the inability of prazosin to alter the NA
output in the DR (Figure 8b).
Modulation of the Effects of Clonidine The lesion with
the noradrenergic neurotoxin DSP-4 significantly attenu-
ated the suppressing effect of local clonidine application
(100 mM) on dialysate 5-HT (F15,270¼ 4.89, po0.000001,
time effect; F15,270¼ 3.52, po0.000015, time group inter-
action) (Figure 9). However, although the effect of the DSP-
4 lesion attenuated the effect on NA output, the change did
not reach statistical significance (Figure 9). These data
clearly indicated that the effects of local clonidine on the 5-
HT release in the DR were dependent on a2-adrenoceptors
located on noradrenergic elements within the DR.
Figure 7 The local application of prazosin (100mM) in the DR of rats lesioned with DSP-4 (40 mg/kg i.p., 5 days before, filled circles, n¼ 10) reduced the 5-HT
output to an extent lesser than in untreated rats (open circles, n¼ 8). The concentration of NA was unaffected in both instances. See text for statistical analysis.
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The lesion with DSP-4 also attenuated the reducing effect
of 0.1 mg/kg clonidine on the DR 5-HT output
(F15,180¼ 4.12, po0.000002, time effect; F15,180¼ 2.73,
po0.0009, time group interaction) (Figure 10a). Likewise,
the electrolytic lesion of the lateral habenula attenuated
the suppressing effect of 0.1 mg/kg clonidine on the
5-HT output (F15,195¼ 4.85, po0.000001, time effect;
F15,195¼ 4.03, po0.000002, time group interaction) (Fig-
ure 10a). In contrast, the effect of clonidine appeared to be
more marked in rats subjected to cortical transection
(n¼ 10), although this difference did not reach statistical
significance (Figure 10a). The DSP-4 lesion attenuated the
effect of clonidine 0.1 mg/kg s.c. on the NA output in the DR
(F15,180¼ 15.57, po0.000001, time effect; F15,180¼ 4.01,
po0.000003, time group interaction) while the lesion of
the lateral habenula or the cortical transection did not alter
the effect of clonidine on NA output (Figure 10b).
Overall, the above data suggested that the suppressant
effect of clonidine on 5-HT release in the DR was because of
different subsets of a2-adrenoceptors, located, respectively,
in the DR and elsewhere in the brain, likely in forebrain
regions that control serotonergic activity indirectly, through
the habenulo–raphe pathway (Aghajanian and Wang, 1977).
The activity of 5-HT neurons is modulated, among others,
by local GABAergic afferents whose inhibitory inputs
appear to vary with anesthesia (Tao and Auerbach, 1994;
Jolas and Aghajanian, 1997). Hence, we next examined the
effect of clonidine on the 5-HT and NA output of chloral
hydrate anesthetized rats. These were subjected to the usual
experimental procedures (see the Materials and methods
section), but the entire experiments were performed under
chloral anesthesia (400 mg/kg i.p. followed by supplemental
doses). In chloral hydrate anesthetized rats (n¼ 7),
clonidine increased the 5-HT output, a change that was
significantly different from that seen in unanesthetized rats
(F1,13¼ 5.70, po0.035, group effect; F15,195¼ 8.87,
po0.000001, group time interaction) (Figure 11a). In
contrast, the effect of clonidine on the NA output did not
differ between awake and anesthetized rats.
Figure 8 (a) Effect of the s.c. administration of prazosin (0.3 mg/kg) on 5-
HT output in the DR in previously untreated rats (open circles) or in (i) rats
pretreated with the noradrenergic neurotoxin DSP-4 (40 mg/kg i.p., 5 days
before) (filled squares), (ii) rats with electrolytic lesions of the lateral
habenula (LHb, filled circles), and (iii) rats with cortical transection (filled
triangles). (b) In all experimental groups, the administration of prazosin left
unaltered the NA concentration. Data from 4 to 8 rats/group. See results
for statistical analysis.
Figure 9 The suppressant effect of local clonidine administration on 5-HT release in the DR was virtually abolished by the pretreatment with DSP-4
(40 mg/kg i.p., 5 days before, filled circles). DSP-4 pretreatment also attenuated the effect of clonidine on NA output, but this effect did not reach statistical
significance. Data from 5 to 11 rats/group. See text for detailed statistical analysis.
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DISCUSSION
Previous work by our group showed that the in vivo release
of 5-HT in the median raphe nucleus is under the control of
a1- and a2-adrenoceptors in this nucleus (Adell and Artigas,
1999). Similarly, microdialysis studies in rat forebrain
revealed that the 5-HT release is also regulated by both
families of a-adrenoceptors (Tao and Hjorth, 1992; Rou-
quier et al, 1994; Bel and Artigas, 1996; Gobert et al, 1998).
Here we extend these previous observations to the control
of the 5-HT release in the DR using both local and systemic
administration of a-adrenoceptor ligands.
Methodological Aspects
The HPLC method employed in this study enabled one to
determine simultaneously the concentration of 5-HT and
NA in brain dialysates. As in previous studies from this and
other groups, citalopram was added to the perfusion fluid.
This aspect was deemed essential for the success of the
study given that (a) 5-HT eluted at a long retention time
(with the consequent reduction in peak height), (b) most
treatments used were expected to markedly reduce 5-HT
release, and (c) the success of fundamental parts of the
study (eg dose–response experiments, effects of lesions)
relied on an accurate discrimination among the 5-HT values
in the various experimental groups. Although 5-HT1A
autoreceptors control 5-HT release in the DR, the concern
on a potential interference of the action of citalopram with
those of the a-adrenoceptor agents used appears unwar-
ranted, in view of the following reasons. First, citalopram
1mM inhibits partially 5-HT reuptake (Herva´s et al, 2000)
and causes little activation of 5-HT1A receptors (Tao et al,
2000). Higher concentrations (typically 410 mM) are
required to activate significantly 5-HT1A receptors and to
reduce 5-HT release (Romero et al, 1994; Tao et al, 2000).
Indeed, despite the large nominal concentrations, the
amount of drugs applied by reverse dialysis at low perfusion
rates is small and the extent of diffusion is very limited (eg
WAY-100635; Celada et al, 2001). Second, 1 mM citalopram
did not interfere with the local or systemic actions of 5-
HT1A receptor ligands on 5-HT release in the midbrain or
forebrain (Casanovas and Artigas, 1996; Adell and Artigas,
Figure 11 (a) In rats anesthetized with chloral hydrate before
microdialysis experiments, the systemic administration of clonidine
(0.1 mg/kg s.c.) increased 5-HT output in the DR (filled squares). (b) The
effect of clonidine on NA output was unaltered by the previous anesthesia.
Data from 4 to 8 rats/group. See text for statistical analysis.
Figure 10 (a) Effect of the s.c. administration of clonidine (0.1 mg/kg) on
5-HT output in the DR in previously untreated rats (open circles) or in (i)
rats pretreated with the noradrenergic neurotoxin DSP-4 (40 mg/kg i.p., 5
days before) (filled squares), (ii) rats with electrolytic lesions of the lateral
habenula (LHb; filled circles), and (iii) rats with cortical transection (filled
triangles).The first two lesion procedures abolished the effects of clonidine
on 5-HT output, whereas the cortical transection exhibited a tendency
towards a greater 5-HT reduction, but this difference did not reach
statistical significance. (b) The effect of clonidine on NA output was only
moderately, but significantly, affected by the DSP-4 lesion. Data from 6 to
10 rats/group. See results for statistical analysis.
Neuropsychopharmacology
5-HT-NA interactions in dorsal raphe
A Bortolozzi and F Artigas
429
1998; Casanovas et al, 1999). Finally, the 5-HT reduction
effected by 0.3 mg/kg prazosin in the presence and absence
of citalopram did not differ.
Overall, these data illustrate that in the experimental
conditions used, dialysate 5-HT and NA concentrations are
representative of a neuronal, impulse-dependent release in
the DR. 5-HT may arise from dendrites but also from the
initial segments of the branching axons, since the DR
contains a dense network of 5-HT efferent fibers (Stein-
busch, 1981; Halliday et al, 1995) whereas dialysate NA
likely originates from the dense plexus of noradrenergic
fibers in the DR (see below). These may release NA in an
impulse-dependent manner, as observed in the forebrain
(L’Heureux et al, 1986). Likewise, most previous reports
support the notion that the 5-HT release in the DR varies in
parallel with serotonergic activity (Casanovas and Artigas,
1996, Casanovas et al, 1997; Matos et al, 1996; Celada et al,
2001). As previously reported in the hippocampus of awake
rats (Done and Sharp, 1994), 8-OH-DPAT increased NA
release in the DR.
Modulation of 5-HT Release by a-Adrenoceptors
The DR receives a dense noradrenergic innervation from
the pontine noradrenergic cell groups (Sakai et al, 1977;
Baraban and Aghajanian, 1980; Peyron et al, 1996).
Neurochemical studies have revealed the presence of
noradrenaline and NA uptake sites in the DR (Saavedra et
al, 1976; Tejani-Butt, 1992; Ordway et al, 1997; Strazielle et
al, 1999). Autoradiographic, immunohistochemical, and in
situ hybridization studies show an abundance of a1-
adrenoceptors in the DR, whereas the presence of a2-
adrenoceptors is not accompanied by their encoding mRNA
(Unnerstall et al, 1984; Pieribone et al, 1994; Nicholas et al,
1996; Rosin et al, 1996; Talley et al, 1996; Day et al, 1997;
Winzer-Serhan et al, 1997a, b). Early studies indicated that
the activity of 5-HT neurons in the DR is under an
excitatory control by a1-adrenoceptors (Baraban and
Aghajanian, 1980; VanderMaelen and Aghajanian, 1983).
In agreement, the a1-adrenoceptor agonist phenylephrine
depolarized DR 5-HT neurons in vitro, an effect blocked by
prazosin (Pan et al, 1994). This, together with the
distribution of cells expressing a1B-adrenoceptors in the
DR (Pieribone et al, 1994; Day et al, 1997), suggests that a1-
adrenoceptors are located on 5-HT neurons. However, to
the best of our knowledge, no detailed histological studies
(ie double immunohistochemical or in situ hybridization)
have been performed to fully confirm this view.
Likewise, the DR also contains a moderate density of a2-
adrenoceptors, as assessed by autoradiography (eg with
[3H]para-aminoclonidine; Unnerstall et al, 1984). Immuno-
histochemical studies also show the presence of a2A- and
a2C-adrenoceptor immunoreactivity in the DR (Rosin et al,
1996; Talley et al, 1996). However, in situ hybridization
studies failed to reveal a significant density of the mRNAs
encoding a2A- and a2C-adrenoceptors in the DR (McCune et
al, 1993; Nicholas et al, 1993, 1996; Scheinin et al, 1994).
This suggests that the majority of a2-adrenoceptors in the
DR are located in noradrenergic terminals where they
function as autoreceptors and control the release of NA.
The local and systemic administration of the a1-adreno-
ceptor antagonist prazosin reduced the 5-HT release in the
DR. Local prazosin (100 mM) virtually suppressed the 5-HT
release, without affecting that of NA. This effect was similar
in magnitude to that of treatments that fully suppress
serotonergic activity, such as TTX or 5-HT1A agonists,
which emphasizes the importance of the noradrenergic
input onto 5-HT neurons for their normal function.
However, it is unclear whether the a1-adrenergic tone in
the DR can be further enhanced. Pilot experiments with
phenylephrine (100 mM in the DR) did not enhance the 5-
HT output (Celada and Artigas, 1993). Given the low
intrinsic efficacy of phenylephrine and the possibility of
nonspecific actions of cirazoline (Ruffolo and Waddell,
1982), in the present study we sought to further enhance the
tone on a1-adrenoceptors with the endogenous transmitter.
To this end, we applied a combination of NA and
desipramine (to prevent its reuptake by noradrenergic
terminals). The inability of this procedure to elevate 5-HT
release suggests that the tone on a1-adrenoceptors is already
maximal in the present experimental conditions, although
we cannot fully exclude that the a1-adrenoceptor-blocking
properties of desipramine may have partly attenuated a
potential NA-induced increase in 5-HT output. Previous
data from this laboratory suggest that the 5-HT output in
the MnR may be further enhanced by cirazoline (Adell and
Artigas, 1999). This would indicate a different regulation of
DR and MnR neurons by a1-adrenoceptors, a view also
supported by the greater reduction in hippocampal 5-HT
release (compared with striatal 5-HT release) after systemic
prazosin administration (Rouquier et al, 1994). However, in
view of the above limitations, a strict regional comparison
of the effect of a1-adrenoceptor stimulation in DR and MnR
is still lacking. Intriguingly, bath addition of phenylephrine
reduced the stimulated 5-HT release in midbrain slices
containing the DR, as assessed by voltammetry (Hopwood
and Stamford, 2001). This observation, at variance with the
widely accepted stimulatory role of a1-adrenoceptors in the
DR (Vandermaelen and Aghajanian, 1983; Pan et al, 1994),
may result from the particular experimental conditions used
(deafferented midbrain slices, high stimulation rates)
(Hopwood and Stamford, 2001).
The inability of the desipramine+NA combination to
increase the 5-HT output in the DR may seem discordant
with the enhancement of 5-HT release produced by the
systemic administration of RX-821002. This agent could
conceivably enhance serotonergic transmission through the
removal of a self-inhibitory effect of NA on noradrenergic
terminals in the DR, thus increasing the release of NA
(Figure 4d) and hence the tone on postsynaptic a1-
adrenoceptors. Indeed, the systemic and intra-raphe
administration of idazoxan, another a2-adrenoceptor an-
tagonist, increased the firing rate of 5-HT neurons in the DR
(Garratt et al, 1991; Hertel et al, 1997). Although this
possibility cannot be fully discarded, it seems unlikely in
view of the different temporal profile of 5-HT and NA
changes after systemic RX 821002 administration (Figures
4c and d). Moreover, RX 821002 is also a 5-HT1A antagonist
(Newman-Tancredi et al, 1998) and could thus contribute to
increase 5-HT release in the DR, as observed with WAY
100635 (Martı´n-Ruiz et al, 2001b). Given that a2-adreno-
ceptors outside the DR also control 5-HT release (see
below), it would be possible that RX 821002 enhanced 5-HT
release by an action at such extra-raphe receptors.
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Interestingly, the reduction of 5-HT release elicited by the
local application of prazosin was more marked than by its
systemic administration (0.3–3 mg/kg s.c.). The comparable
effects of 0.3 and 1 mg/kg suggest that this was a nearly
maximal effect, whereas 3 mg/kg appeared to be less
effective. Interestingly, a similar dose range (0.1–1 mg/kg
s.c.) reduced dose-dependently the 5-HT output in ventral
hippocampus to a maximum of 30% of baseline (Hjorth et
al, 1995). Lower i.v. doses (0.03–0.4 mg/kg) also induced a
marked reduction of hippocampal 5-HT output (Rouquier
et al, 1994). The local-systemic difference in the present
study cannot be ascribed to an unusually marked effect of
the local application, since two different experiments
performed several months apart gave identical results.
Thus, the possibility exists that prazosin may additionally
modulate DR serotonergic activity and 5-HT release by a1-
adrenoceptors outside the DR, whose blockade would
oppose that in the DR, thus resulting in an attenuated
effectiveness of the systemic administration.
The lateral habenula and the medial prefrontal cortex are
two forebrain structures that densely innervate the DR and
control the activity of 5-HT neurons in this nucleus
(Aghajanian and Wang, 1977; Stern et al, 1981; Sesack et
al, 1989; Takagishi and Chiba, 1991; Hajo´s et al, 1998;
Peyron et al, 1998; Celada et al, 2001; Martı´n-Ruiz et al,
2001a). The density of the various a-adrenoceptor subtypes
in the lateral habenula ranges from none to moderate
(Unnerstall et al, 1984; Pieribone et al, 1994; Rosin et al,
1996; Day et al, 1997; Winzer-Serhan et al, 1997a,b).
However, several areas rich in a1- and a2-adrenoceptors
projecting to the lateral habenula, such as the hippocampus
or the amygdala (Matthews-Felton et al, 1999), contain a
high density of both a-adrenoceptor families. Likewise,
all cortical layers in the frontal cortex contain a moderate
to high density of a-adrenoceptors (Unnerstall et al,
1984; Pieribone et al, 1994; Rosin et al, 1996; Day et al,
1997; Winzer-Serhan et al, 1997a,b) that could be involved
in the distal control of serotonergic activity and 5-HT
release, as shown for cortical (prefrontal) 5-HT1A and 5-
HT2A receptors (Ceci et al, 1994; Hajo´s et al, 1999; Celada
et al, 2001; Martı´n-Ruiz et al, 2001a; Martı´n-Ruiz and
Ugedo, 2001). Likewise, the medial prefrontal cortex
controls the activity of locus coeruleus noradrenergic
neurons (Jodo et al, 1998), which in turn might affect
5-HT neurons in the DR.
To examine the influence of such distal influences, we
performed lesion experiments, that is, bilateral electrolytic
lesions of the lateral habenula and cortical transections.
Furthermore, groups of rats were treated with the selective
noradrenergic neurotoxin DSP-4 to assess whether the
effects of clonidine and prazosin were dependent on the
noradrenergic input onto DR 5-HT neurons.
Contrary to our initial assumption, neither the cortical
transection nor the electrolytic lesion of the lateral habenula
significantly modified the suppressant effects of 0.3 mg/kg
prazosin on 5-HT release in the DR. The lesion with DSP-4
attenuated the suppressant effect of the local (but not
systemic) prazosin administration. The lower effect of local
prazosin in DSP-4-treated rats may reflect a diminished
tone on a1-adrenoceptors on 5-HT neurons (ie resulting
from damaged noradrenergic terminals) or be the result of
adaptive pre- and postsynaptic mechanisms secondary to
the loss of noradrenergic fibers. In support of the latter
possibility is the observation that the NA output in the DR
was increased in DSP-4-lesioned rats, perhaps as a
compensatory mechanism to the massive loss of tissue NA
and noradrenergic terminals. A lack of reduction of NA
release after DSP-4 treatment has also been reported in rat
frontal cortex (Kask et al, 1997).
The similar reduction elicited by 0.3 mg/kg prazosin in
untreated and DSP-4 lesioned rats suggests that the
blockade of a1-adrenoceptors in the DR produced by this
systemic dose is lower than that produced by its local
application and/or that different receptor populations are
being affected by both procedures. The inherent complexity
of in vivo microdialysis prevented the realization of a full
dose–response study after these lesion procedures. Hence, it
cannot be discarded that the above lesions might alter the
effect of higher doses of prazosin (eg 3 mg/kg) that appeared
to elicit an abnormally low effect on 5-HT release.
The local and systemic administration of clonidine
reduced the in vivo 5-HT release in the DR, as previously
observed in the MnR and forebrain areas (Tao and Hjorth,
1992; Bel and Artigas, 1996; Adell and Artigas, 1999). The
clonidine-induced 5-HT reductions (local and systemic)
were more moderate than those elicited by prazosin, maybe
because of the partial agonist properties of clonidine. Unlike
prazosin, systemic clonidine reduced 5-HT release more
than its local application. The local effect possibly involves
the activation of a2-adrenoceptors on noradrenergic term-
inals that synapse on and activate 5-HT neurons through a1-
adrenoceptors. The systemic action of clonidine likely
involves also somatodendritic a2-autoreceptors in the
pontine nuclei, whose activation should result in the
observed reduction of NA release, and hence of the tone
on postsynaptic a1-adrenoceptors on 5-HT neurons. Ad-
ditionally, clonidine might reduce 5-HT release in the DR
via the activation of a2-heteroceptors on 5-HT axonal
varicosities within this nucleus. This mechanism has been
assumed to underlie in part the action of clonidine on the 5-
HT system in forebrain (Tao and Hjorth, 1992; Bel and
Artigas, 1996; Mongeau et al, 1997) and DR (Hopwood and
Stamford, 2001). However, the lesion with DSP-4 virtually
abolished the effects of local clonidine on 5-HT release,
which suggests that, when applied in the DR, it acts
predominantly on a2-autoreceptors. Likewise, the effect of
the systemic administration of clonidine on 5-HT release
depends, among other factors, on the integrity of NA
neurons (ie somatodendritic and terminal a1-adrenocep-
tors) as it was also cancelled by the previous lesion with
DSP-4. However, because the DR contains a dense network
of 5-HT fibers, a2-heteroceptors might also contribute,
as suggested by voltammetric studies (Hopwood and
Stamford, 2001).
The effect of systemic clonidine administration on 5-HT
(but not NA) release was also cancelled by the lesion of the
lateral habenula and appeared to be more marked (although
not significantly) in rats subjected to cortical transection. In
a small number of rats, the lesion of the lateral habenula
with kainic acid also abolished the effect of clonidine on 5-
HT release (unpublished observations). These rats also had
a massive loss of hippocampal tissue, as a result of the
proximity of the injection site and the sensitivity of
hippocampal neurons to kainic acid. Moreover, clonidine
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increased 5-HT (but not NA) release in rats anesthetized
with chloral hydrate, suggesting that in this condition the
effect of clonidine on 5-HT release opposed that produced
through the activation of a2-adrenoceptors on noradrener-
gic neurons. The effect of anesthesia may be because of a
putative change of inhibitory inputs onto 5-HT neurons, as
observed with morphine and baclofen, two drugs affecting
5-HT release in the DR via GABAergic interneurons (Tao
and Auerbach, 1994; Jolas and Aghajanian, 1997; Abellan et
al, 2000). Thus, the chloral hydrate-induced prevention of
the effect of clonidine possibly reflects the existence of a2-
adrenoceptors in areas that project to 5-HT neurons in the
DR via GABAergic afferents or local interneurons. Indeed,
early observations in chloral hydrate anesthetized rats
already suggested a complex action of clonidine on 5-HT
neurons. Thus, low i.v. doses reduced the firing rate of 5-HT
neurons, yet this effect disappeared at higher doses
(Svensson et al, 1975). Moreover, although bath application
of NA excites and clonidine inhibits 5-HT neurons in the
slice preparation (Alojado et al, 1994) the microiontophore-
tic application of clonidine in the DR did not suppress the
firing of 5-HT neurons (Dresse and Scuvee-Moreau, 1986).
Our results give support to the notion that the action of
clonidine on 5-HT release is indirect. In the DR, a2-
adrenoceptors responsible for this effect appear to be
located on noradrenergic terminals, although a2-hetero-
ceptors may also participate (Hopwood and Stamford,
2001). Moreover, based on lesion studies and the interaction
of anesthesia with the effect of clonidine on 5-HT release,
we propose the involvement of a2-adrenoceptors on other
brain areas, although we cannot clarify which of the various
candidate forebrain structures is involved. Interestingly,
neither lesion procedure nor anesthesia (with the exception
of DSP-4, discussed above) altered the effect of clonidine on
NA output, which supports a direct action of clonidine on
NA neurons and emphasizes the indirect nature of the effect
on 5-HT neurons.
In summary, the present results support the notion that
the 5-HT release in the DR is strongly dependent on the
activation of a1-adrenoceptors in this nucleus. The tone on
such receptors appears to be maximal in the experimental
conditions used (daylight, unanesthetized rats). Likewise,
the activation of a2-adrenoceptors in the DR reduces the
release of 5-HT, although to a lesser extent than the
blockade of a1-adrenoceptors. This effect is predominantly
mediated by a2-autoreceptors located on noradrenergic
terminals, since it is dependent on the integrity of
noradrenergic neurons. Finally, based on the discrepancies
between the local and systemic effects of prazosin and
clonidine and on the results of lesion studies, we suggest
that a-adrenoreceptors outside the DR are involved in the
control of 5-HT release in the DR as well.
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